Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of oral CAD-1883 in healthy volunteers
NL-OMON46676Phase 1Active, not recruiting
- Sponsor
- Cadent Therapeutics
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in spinocerebellar ataxia (SCA) and essential tremor (ET) comparing CAD-1883 with Placebo (2 arms). Primary endpoints: Safety and tolerability, Pharmacokinetics and 2 more. Started Jan 2018; status: active, not recruiting.
02
Drugs
rimtuzalcap
03
Conditions
spinocerebellar ataxia (SCA)essential tremor (ET)
Beyond the preview
Go deeper on NL-OMON46676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46676.